Laurent Bertoletti Highlights Evolving Role of Anticoagulation in Pulmonary Hypertension Treatment
Laurent Bertoletti, University Professor and Hospital Practitioner at Jean Monnet University, Saint-Etienne, shared on LinkedIn:
”Thank you to the scientific council of the French Days of Pulmonary Hypertension RespiFil for the invitation to present an update on the treatment anticoagulant in pulmonary hypertension.
It is an honour to be able to share data from the French registry and to discuss a topic that is as debated as it is crucial for patient care.
The prescription of anticoagulants now seems to be restricted to patients with a validated indication such as a history of MTEV or atrial fibrillation.
The next collective objective is to determine the best therapeutic antithrombotic strategy, in patients with PH-TEC or PH and a validated indication.”
Stay updated with Hemostasis Today.
-
Mar 12, 2026, 17:06Caitlin Raymond: Managing Crigler–Najjar Syndrome Type 1 Crisis Without a Standard TPE Protocol
-
Mar 12, 2026, 17:03Jan Sloves: Insights on Comprehensive Venous Duplex Imaging at VEITH Symposium 2025
-
Mar 12, 2026, 16:36Giordano Botta: From the ‘Power of Zero’ to a Precise Understanding of Cardiovascular Risk
-
Mar 12, 2026, 16:31Katie Baca-Motes: Incorporating Menstrual Cycle and Hormonal Rhythms Into Clinical Research
-
Mar 12, 2026, 16:22Augustina Isioma Ikusemoro: Quality Indicators in Processed Blood Components
-
Mar 12, 2026, 16:20Aryabhatta Sadhu: The Full Spectrum of Transplant Immunology and Clinical Care
-
Mar 12, 2026, 16:17Megan Adediran: Building Pathways to Sustainable Care for People With Bleeding Disorders in Nigeria
-
Mar 12, 2026, 16:09Rob Mac Sweeney: Hemodynamic Failure During Sepsis
-
Mar 12, 2026, 16:06Haroun Gajraj: Shortwave Diathermy for Facial Spider Veins